Valuation: ICAD

Market Cap 106M 92.27M 84.73M 79.01M 150M 10.05B 152M 1.02B 395M 4.93B 396M 388M 16.99B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 77.55M 71.21M 66.41M 126M 8.45B 128M 857M 332M 4.14B 333M 326M 14.28B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
1 year 3.68
Extreme 3.68
3.99
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
17.3
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 2023-03-09
Director of Finance/CFO 54 2025-07-16
Corporate Secretary - 2025-07-16
Date Insider Type Main position Quantity % Market Cap.
25-07-16Issuer sale

Chief Technology Officer

351,145 1.3231%
25-07-16Issuer sale

Director

82,056 0.3092%
25-07-16Issuer sale

Chief Executive Officer

519,350 1.9569%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%+4.03%+137.42% 106M
+1.23%+2.99%+21.77%+0.34% 191B
+4.81%+5.60%-21.93%+25.60% 143B
+1.02%+1.72%-2.95%-17.01% 137B
+4.17%+1.61%-56.66%-16.12% 64B
+2.10%+4.71%+21.97%+2.68% 52.97B
+1.39%+1.63%-26.28%-31.02% 43.82B
-1.46%-2.85%+9.10%+10.33% 37.67B
-1.14%-0.66%+6.38%+41.40% 37.13B
+0.45%+0.37%-14.37%-19.22% 29.5B
Average +1.60%+2.13%-5.89%+13.44% 73.56B
Weighted average by Cap. +1.90%+3.37%-3.85%+0.69%

Financials

2023 2024
Net sales 17.32M 15.13M 13.9M 12.96M 24.57M 1.65B 24.98M 167M 64.84M 809M 65.03M 63.61M 2.79B 19.61M 17.13M 15.73M 14.67M 27.82M 1.87B 28.28M 189M 73.41M 916M 73.62M 72.02M 3.15B
Net income -4.85M -4.24M -3.89M -3.63M -6.88M -461M -6.99M -46.83M -18.15M -226M -18.2M -17.8M -780M -5.62M -4.91M -4.51M -4.2M -7.97M -535M -8.1M -54.26M -21.03M -262M -21.09M -20.63M -904M
Net Debt -21.21M -18.53M -17.02M -15.87M -30.09M -2.02B -30.59M -205M -79.41M -990M -79.64M -77.9M -3.41B -16.84M -14.72M -13.52M -12.6M -23.89M -1.6B -24.3M -163M -63.07M -787M -63.25M -61.87M -2.71B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock